When Orphan Drugs Make All the Difference

Published: Mar 3, 2016
Only 5% of rare diseases have treatments. What difference does that make to patients?

Orphan drugs are growing in importance worldwide. However, bringing an orphan drug to market unique challenges and considerations. Overcoming these challenges requires the cooperation of clinical trial investigators, drug manufacturers, local and national governments and more.

This article will discuss:

  • Where to start in overcoming these challenges
  • Possible secondary and more profitable use of an orphan drug
  • The process of holding clinical trials
  • Ethical and practical considerations
Author
Sue Lee
Sue Lee
Technical Portfolio Manager
World Courier

With her career at World Courier spanning more than 25 years, Sue Lee has served in a variety of customer service and operational functions, including in the establishment of numerous multinational clinical studies and in the transportation of biological samples and pharmaceutical supplies to a host of challenging locations. In her current role, Lee oversees the delivery of pertinent technical information and updates on the latest industry developments.